383 related articles for article (PubMed ID: 33607382)
1. Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis.
Deng A; Wang C; Cohen SJ; Winter JM; Posey J; Yeo C; Basu Mallick A
Eur J Cancer; 2021 Apr; 147():17-28. PubMed ID: 33607382
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant therapy versus upfront surgery for early-stage left-sided pancreatic adenocarcinoma: A propensity-matched analysis from a national cohort of distal pancreatectomies.
Nassour I; Adam MA; Kowalsky S; Al Masri S; Bahary N; Singhi AD; Lee K; Zureikat A; Paniccia A
J Surg Oncol; 2021 Jan; 123(1):245-251. PubMed ID: 33103242
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM
J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388
[TBL] [Abstract][Full Text] [Related]
4. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
[TBL] [Abstract][Full Text] [Related]
5. Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base.
Mirkin KA; Hollenbeak CS; Wong J
Int J Surg; 2016 Oct; 34():96-102. PubMed ID: 27573691
[TBL] [Abstract][Full Text] [Related]
6. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis.
de Geus SW; Eskander MF; Bliss LA; Kasumova GG; Ng SC; Callery MP; Tseng JF
Surgery; 2017 Mar; 161(3):592-601. PubMed ID: 28341441
[TBL] [Abstract][Full Text] [Related]
8. Completion of Adjuvant Chemotherapy After Upfront Surgical Resection for Pancreatic Cancer Is Uncommon Yet Associated With Improved Survival.
Altman AM; Wirth K; Marmor S; Lou E; Chang K; Hui JYC; Tuttle TM; Jensen EH; Denbo JW
Ann Surg Oncol; 2019 Nov; 26(12):4108-4116. PubMed ID: 31313044
[TBL] [Abstract][Full Text] [Related]
9. Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience.
Rangelova E; Wefer A; Persson S; Valente R; Tanaka K; Orsini N; Segersvärd R; Arnelo U; Del Chiaro M
Ann Surg; 2021 Mar; 273(3):579-586. PubMed ID: 30946073
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy is associated with improved survival in patients with left-sided pancreatic adenocarcinoma.
Ocuin LM; Hardacre JM; Ammori JB; Rothermel LD; Mohamed A; Selfridge JE; Bajor D; Winter JM
J Surg Oncol; 2020 Dec; 122(8):1595-1603. PubMed ID: 32844445
[TBL] [Abstract][Full Text] [Related]
11. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Hospital Neoadjuvant Therapy Utilization on Survival Outcomes for Pancreatic Cancer.
Fisher AV; Abbott DE; Venkatesh M; Leverson GE; Campbell-Flohr SA; Ronnekleiv-Kelly SM; Greenberg CC; Winslow ER; Weber SM
Ann Surg Oncol; 2018 Sep; 25(9):2661-2668. PubMed ID: 30003452
[TBL] [Abstract][Full Text] [Related]
13. Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodenectomy.
Hue JJ; Sugumar K; Markt SC; Hardacre JM; Ammori JB; Rothermel LD; Winter JM; Ocuin LM
Surgery; 2021 Jul; 170(1):207-214. PubMed ID: 33454134
[TBL] [Abstract][Full Text] [Related]
14. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.
Hank T; Sandini M; Ferrone CR; Rodrigues C; Weniger M; Qadan M; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
JAMA Surg; 2019 Oct; 154(10):943-951. PubMed ID: 31411659
[TBL] [Abstract][Full Text] [Related]
15. Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head.
Lutfi W; Talamonti MS; Kantor O; Wang CH; Liederbach E; Stocker SJ; Bentrem DJ; Roggin KK; Winchester DJ; Marsh R; Prinz RA; Baker MS
Surgery; 2016 Sep; 160(3):714-24. PubMed ID: 27422328
[TBL] [Abstract][Full Text] [Related]
16. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study.
Lof S; Korrel M; van Hilst J; Alseidi A; Balzano G; Boggi U; Butturini G; Casadei R; Dokmak S; Edwin B; Falconi M; Keck T; Malleo G; de Pastena M; Tomazic A; Wilmink H; Zerbi A; Besselink MG; Abu Hilal M;
Ann Surg Oncol; 2020 Jun; 27(6):1986-1996. PubMed ID: 31848815
[TBL] [Abstract][Full Text] [Related]
17. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
[TBL] [Abstract][Full Text] [Related]
18. Can we eliminate neoadjuvant chemoradiotherapy in favor of neoadjuvant multiagent chemotherapy for select stage II/III rectal adenocarcinomas: Analysis of the National Cancer Data base.
Cassidy RJ; Liu Y; Patel K; Zhong J; Steuer CE; Kooby DA; Russell MC; Gillespie TW; Landry JC
Cancer; 2017 Mar; 123(5):783-793. PubMed ID: 27780316
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of adjuvant chemotherapy following neoadjuvant chemotherapy and resection for borderline resectable and locally advanced pancreatic cancer.
Zhang C; Wu R; Smith LM; Baine M; Lin C; Reames BN
Am J Surg; 2022 Jul; 224(1 Pt A):51-57. PubMed ID: 34973686
[TBL] [Abstract][Full Text] [Related]
20. Value of lymph node positivity in treatment planning for early stage pancreatic cancer.
Tran Cao HS; Zhang Q; Sada YH; Silberfein EJ; Hsu C; Van Buren G; Chai C; Katz MHG; Fisher WE; Massarweh NN
Surgery; 2017 Sep; 162(3):557-567. PubMed ID: 28666686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]